NDA 202834 · Catalyst Pharms
Fycompa
Perampanel · Oral · Noncompetitive AMPA Glutamate Receptor Antagonist
NovelLast checked: Nov 20, 2026Latest source record: Dec 5, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Oct 22, 2012
Approved uses
4
Original approval plus efficacy supplements
Registered trials
83
18 Phase 3, 6 recruiting
FAERS reports
7,728
6,392 serious, 472 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation and threats have been reported in patients taking FYCOMPA ( 5.1 ). These reactions occurred in patients with and without prior psychiatric history, prior aggressive behavior, or concomitant use of medications associated with hostility and aggression ( 5.1 ). Advise patients and caregivers to contact a healthcare provider immediately if any of these reactions or changes in mood, behavior, or personality that are not typical for the patient are observed while taking FYCOMPA or after discontinuing FYCOMPA ( 5.1 ). Closely monitor patients particularly during the titration period and at higher doses ( 5.1 ). FYCOMPA should be reduced if these symptoms occur and should be discontinued...
What it is approved for
From the label in effect Jan 5, 2024.
FYCOMPA, a non-competitive AMPA glutamate receptor antagonist, is indicated for: Treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older ( 1.1 ) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older ( 1.2 ) 1.1 Partial-Onset Seizures FYCOMPA is indicated for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older. 1.2 Primary Generalized Tonic-Clonic Seizures FYCOMPA is indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 27, 2018 Supplement 14 · Efficacy · priority review LetterLabelMedication Guide
- Jul 26, 2017 Supplement 12 · Efficacy LetterLabelMedication Guide
- Jun 19, 2015 Supplement 5 · Efficacy Pediatric Statistical ReviewPediatric Medical ReviewPediatric Medical Review
- Oct 22, 2012 Original approval · Type 1 - New Molecular Entity NovelLabelPediatric Clinical Pharmacology ReviewPediatric Statistical Review
6 products under this application
- FYCOMPA · PERAMPANEL 10MG · TABLET, ORAL · Prescription · TE AB
- FYCOMPA · PERAMPANEL 6MG · TABLET, ORAL · Prescription · TE AB
- FYCOMPA · PERAMPANEL 2MG · TABLET, ORAL · Prescription · TE AB
- FYCOMPA · PERAMPANEL 12MG · TABLET, ORAL · Prescription · TE AB
- FYCOMPA · PERAMPANEL 8MG · TABLET, ORAL · Prescription · TE AB
- FYCOMPA · PERAMPANEL 4MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Perampanel" as an intervention, any sponsor and status, largest first.
- Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial SeizuresPivotal-lookingCompleted
Eisai Inc.Eisai
NCT00735397 · 1,218 participants · Start Oct 2008 · Primary completion Sep 2014
Drug: perampanel · For: Epilepsy
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 239 sites in all
- A Study of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsPivotal-lookingTerminated
Eisai Inc.Eisai
NCT00360412 · 997 participants · Start Oct 2006 · Primary completion Apr 2008
Drug: E2007 · For: Parkinson's Disease
Sites: Marburg, Germany
- A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset SeizuresPivotal-lookingCompleted
Eisai Co., Ltd.Eisai
NCT01618695 · 940 participants · Start May 15, 2012 · Primary completion Sep 15, 2014
Drug: Perampanel; Placebo · For: Partial-onset Seizures
Sites: Bedford Park, Australia; Camperdown, Australia; Clayton, Australia · 117 sites in all
- Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsPivotal-lookingCompleted
Eisai Inc.Eisai
NCT00368108 · 752 participants · Start Aug 2006 · Primary completion Jan 2008
Drug: 2 mg perampanel; 4 mg perampanel and 1 more · For: Parkinson's Disease
Sites: Birmingham, Alabama; Huntsville, Alabama; Peoria, Arizona · 114 sites in all
- Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsPivotal-lookingTerminated
Eisai LimitedEisai
NCT00360308 · 723 participants · Start Nov 2006 · Primary completion Apr 2008
Drug: Placebo; E2007 and 1 more · For: Parkinson's Disease
Sites: Toulouse, France
- Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial SeizuresPivotal-lookingCompleted
Eisai Inc.Eisai
NCT00700310 · 712 participants · Start Aug 2008 · Primary completion Aug 2009
Drug: perampanel; perampanel and 2 more · For: Refractory Partial Seizures
Sites: Woodville, Australia; Woodville South, Australia; Clayton, Australia · 137 sites in all
- The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsPivotal-lookingCompleted
Eisai LimitedEisai
NCT00286897 · 702 participants · Start Feb 2006 · Primary completion Jun 2007
Drug: E2007 · For: Parkinson's Disease
Sites: Innsbruck, Austria; Vienna, Austria; Brussels, Belgium · 118 sites in all
- Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial SeizuresPivotal-lookingCompleted
Eisai Inc.Eisai
NCT00699972 · 390 participants · Start Apr 30, 2008 · Primary completion Oct 19, 2010
Drug: E2007 (perampanel); E2007 (perampanel) and 1 more · For: Refractory Partial Seizures
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 97 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- seizure1,171
- drug ineffective1,129
- off label use830
- somnolence525
- aggression504
- dizziness408
- epilepsy377
- status epilepticus350
- drug interaction343
- multiple-drug resistance332
- fatigue316
- irritability253
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 8 |
| 2013 | 16 |
| 2014 | 183 |
| 2015 | 275 |
| 2016 | 332 |
| 2017 | 455 |
| 2018 | 572 |
| 2019 | 705 |
| 2020 | 664 |
| 2021 | 779 |
| 2022 | 668 |
| 2023 | 765 |
| 2024 | 908 |
| 2025 | 884 |
| 2026 | 514 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Fycompa (Perampanel)
2024 spending
$75.7M
Beneficiaries
6,558
59,762 claims
Per beneficiary
$11,544
$37.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $51,630,237 |
| 2021 | $57,404,778 |
| 2022 | $65,621,224 |
| 2023 | $72,036,496 |
| 2024 | $75,702,972 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review.
Steinhoff BJ, Klein P, Klitgaard H, et al. · Epilepsy Behav 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Palliative care and end-of-life care in adults with malignant brain tumors.
Koekkoek JAF, van der Meer PB, Pace A, et al. · Neuro Oncol 2023 · Systematic Review
- Antiseizure medications for idiopathic generalized epilepsies: a systematic review and network meta-analysis.
Chu H, Zhang X, Shi J, et al. · J Neurol 2023 · Systematic Review, Network Meta-Analysis
- Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis.
Lattanzi S, Trinka E, Zaccara G, et al. · Drugs 2022 · Systematic Review, Network Meta-Analysis
- Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force.
Tomson T, Battino D, Bromley R, et al. · Epileptic Disord 2022 · Systematic Review
- Perampanel add-on for drug-resistant focal epilepsy.
Bresnahan R, Hill RA, Wang J · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
Sponsor: Catalyst Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.